Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · May 17, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring how effective ultrasound is in detecting a condition called peripheral neuropathy, which can occur in patients with gastrointestinal cancers, particularly colorectal cancer, who are treated with a chemotherapy drug called oxaliplatin. Peripheral neuropathy can cause symptoms like numbness, tingling, or pain in the hands and feet, and this study aims to see if ultrasound can help doctors identify this issue more accurately in patients receiving this treatment.

If you or a loved one has gastrointestinal cancer, especially colorectal cancer, and has been treated with oxaliplatin, you might be eligible to participate in this trial. Participants will need to have symptoms of peripheral neuropathy noted in their medical records. However, individuals who had nerve issues before starting oxaliplatin treatment cannot join. Those who participate can expect to undergo ultrasound tests, which are safe and non-invasive, to help better understand the effects of oxaliplatin on their nerves. The trial is currently recruiting participants aged 65 to 74, and it’s a great opportunity to contribute to important research that could improve care for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gastrointestinal cancer
• • Colorectal cancer (any stage)
• • Previously or currently receiving oxaliplatin -based chemotherapy.
• • Clinical symptoms of peripheral neuropathy noted in medical record and suspected to be secondary to oxaliplatin -based therapy.
• • Ability and willingness to understand and sign an informed consent.
• Exclusion Criteria:
• • Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of oxaliplatin chemotherapy.
• • Unable to provide history.